Human ES-derived cardiomyocytes regenerate non-human primate hearts

ceazon

2 \! [) }  ~* D% w$ M) H, t; `; L4 v. U. h8 v( g( _
8 N2 Y6 `9 A9 D, G5 V" k
! J2 e# f. l/ P+ \
Human embryonic-stem-cell-derived cardiomyocytes regenerate non-human primate hearts2 Z3 w4 @1 }& \# M( C9 f

1 ^6 r( T; J7 r9 \2 s 2 W' Z( j; }! P! C& y

, Z- w2 L) ?6 {3 _' @4 IPluripotent stem cells provide a potential solution to current epidemic rates of heart failure1 by providing human cardiomyocytes to support heart regeneration2. Studies of human embryonic-stem-cell-derived cardiomyocytes (hESC-CMs) in small-animal models have shown favourable effects of this treatment. However, it remains unknown whether clinical-scale hESC-CM transplantation is feasible, safe or can provide sufficient myocardial regeneration. Here we show that hESC-CMs can be produced at a clinical scale (more than one billion cells per batch) and cryopreserved with good viability. Using a non-human primate model of myocardial ischaemia followed by reperfusion, we show that that cryopreservation and intra-myocardial delivery of one billion hESC-CMs generates extensive remuscularization of the infarcted heart. The hESC-CMs showed progressive but incomplete maturation over a 3-month period. Grafts were perfused by host vasculature, and electromechanical junctions between graft and host myocytes were present within 2 weeks of engraftment. Importantly, grafts showed regular calcium transients that were synchronized to the host electrocardiogram, indicating electromechanical coupling. In contrast to small-animal models7, non-fatal ventricular arrhythmias were observed in hESC-CM-engrafted primates. Thus, hESC-CMs can remuscularize substantial amounts of the infarcted monkey heart. Comparable remuscularization of a human heart should be possible, but potential arrhythmic complications need to be overcome.

cortex

原文

bubble_w

求原文